Keros Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KROS research report →
Range $18 – $23
Price Chart
About the company
Keros Therapeutics, Inc. , a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis.
- CEO
- Jasbir S. Seehra
- IPO
- 2020
- Employees
- 92
- HQ
- Lexington, MA, US
Get TickerSpark's AI analysis on KROS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $242.49M
- P/E
- -3.03
- PEG
- 0.00
- P/S
- 14.80
- P/B
- 0.85
- EV/EBITDA
- 0.23
- Div Yield
- 0.00%
- Gross Margin
- 94.68%
- Op Margin
- -675.82%
- Net Margin
- -553.88%
- ROE
- -21.40%
- ROIC
- -35.25%
Latest fiscal year · YoY change
- Revenue
- $244.06M+6775.0%
- Gross Profit
- $242.55M+6732.5%
- Op Income
- $70.62M
- Net Income
- $87.01M+146.4%
- EPS
- $2.34+146.8%
- OCF Growth
- +166.8%
- FCF Growth
- +165.1%
- 52W High
- $22.55
- 52W Low
- $9.69
- 50D MA
- $11.04
- 200D MA
- $12.73
- Beta
- 1.02
- RSI (14)
- 62
- Avg Volume
- 194.05K
No earnings-call transcripts are available for KROS yet.
- Free Float
- 92.3%
- Shares Outstanding
- 19.83M
- Float Shares
- 29.53M
of shares held by institutions
134 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 2.79M | ▲ 382.42K |
| Vanguard Group Inc | 1.53M | ▼ 1.19M |
| Nantahala Capital Management, LLC | 1.41M | ▲ 50.00K |
| Aqr Capital Management LLC | 967.86K | ▲ 561.30K |
| Vanguard Capital Management LLC | 833.60K | ▲ 2.17K |
| Orbimed Advisors LLC | 759.15K | 0 |
| Federated Hermes, Inc. | 700.43K | ▲ 11.20K |
| Vanguard Portfolio Management LLC | 652.63K | ▼ 29.41K |
| Mackenzie Financial Corp | 628.44K | ▲ 475.99K |
| Madison Avenue Partners, LP | 626.58K | 0 |
| Qube Research & Technologies Ltd | 608.84K | ▼ 116.09K |
| Jacobs Levy Equity Management, Inc | 605.45K | ▼ 100.63K |
Held by 154 ETFs
Biggest fund positions in KROS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 18, 26 | Tanini Annita | sell | 1,224 |
| Aug 18, 26 | Lerner Lorena Raquel | sell | 3,568 |
| Aug 18, 26 | Cho Esther | sell | 4,485 |
| Aug 18, 26 | Newton Charles W. | sell | 551 |
| Aug 17, 26 | BIENAIME JEAN JACQUES | buy | 1,000 |
| Aug 4, 26 | Tanini Annita | other | 0 |
| Aug 4, 26 | Tanini Annita | other | 7,500 |
| Aug 4, 26 | Tanini Annita | other | 25,000 |
| Aug 4, 26 | Tanini Annita | other | 6,000 |
| Aug 4, 26 | Tanini Annita | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KROS coverage
Recent articles, reports, and earnings notes.
No research on KROS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KROS report →Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)
defenseworld.net · Oct 5
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
zacks.com · Sep 29
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
globenewswire.com · Sep 29
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
globenewswire.com · Sep 28
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
globenewswire.com · Sep 8
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
zacks.com · Sep 2
Hsbc Holdings PLC Makes New $761,000 Investment in Keros Therapeutics, Inc. $KROS
defenseworld.net · Sep 2
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
zacks.com · Aug 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.